| Literature DB >> 22915778 |
Ji-Yeon Park1, Jeong-Woo Lee, Jin-Beom Chung, Kyoung-Sik Choi, Yon-Lae Kim, Byung-Moon Park, Youhyun Kim, Jungmin Kim, Jonghak Choi, Jae-Sung Kim, Semie Hong, Tae-Suk Suh.
Abstract
A bio-anatomical quality assurance (QA) method employing tumor control probability (TCP) and normal tissue complication probability (NTCP) is described that can integrate radiobiological effects into intensity-modulated radiation therapy (IMRT). We evaluated the variations in the radiobiological effects caused by random errors (r-errors) and systematic errors (s-errors) by evaluating TCP and NTCP in two groups: patients with an intact prostate (G(intact)) and those who have undergone prostatectomy (G(tectomy)). The r-errors were generated using an isocenter shift of ±1 mm to simulate a misaligned patient set-up. The s-errors were generated using individual leaves that were displaced inwardly and outwardly by 1 mm on multileaf collimator field files. Subvolume-based TCP and NTCP were visualized on computed tomography (CT) images to determine the radiobiological effects on the principal structures. The bio-anatomical QA using the TCP and NTCP maps differentiated the critical radiobiological effects on specific volumes, particularly at the anterior rectal walls and planning target volumes. The s-errors showed a TCP variation of -40-25% in G(tectomy) and -30-10% in G(intact), while the r-errors were less than 1.5% in both groups. The r-errors for the rectum and bladder showed higher NTCP variations at ±20% and ±10%, respectively, and the s-errors were greater than ±65% for both. This bio-anatomical method, as a patient-specific IMRT QA, can provide distinct indications of clinically significant radiobiological effects beyond the minimization of probable physical dose errors in phantoms.Entities:
Mesh:
Year: 2012 PMID: 22915778 PMCID: PMC3483850 DOI: 10.1093/jrr/rrs049
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Plan parameters and beam delivery technique in IMRT plan simulations
| Patients | Beam delivery | Prescription | CTVa-to-PTVb margin | Internal immobilization |
|---|---|---|---|---|
| Intact prostate (Gintact) | 15 MV photon beams 5 fields (200°, 270°, 340°, 60°, 120°), Step-and-shoot | 70 Gy, 35 fr.c | CTV (including seminal vesicle) + 10 mm, but 5 mm for posterior wall of the prostate | Rectal balloons filled with 70 cm3 air |
| Prostatectomy (Gtectomy) | 15 MV photon beams 7 fields (220°, 260°, 310°, 0°, 50°, 100°, 140°), Step-and-shoot | 78 Gy, 39 fr. | CTV + 10 mm, but 5 mm for posterior wall of the prostate | Rectal balloons filled with 70 cm3 air |
aCTV: clinical target volume; bPTV: planning target volume; cfr.: fractions.
Variable symbols and their meanings for the biophysical evaluation equations
| Parameters | Definition | Equations |
|---|---|---|
| Di | Delivered dose to the | (1) |
| vi | Corresponding volume of | |
| Dp | Prescribed dose | |
| VT | Total target volume | (1), (2) |
| VRI | Corresponding volume to the reference isodose | (2) |
| VT,RI | Target volume covered by the reference isodose | |
| n | Total fraction number | (3) |
| di | Delivered fractional dose on | |
| df | Reference dose per fraction | |
| α/β | The parameter of a linear quadratic model | |
| R | The region composed of i-th subvolumes | (5), (6) |
| γ50 | The normalized slope at the 50% tumor control probability | |
| TCD50 | Dose required to achieve 50% tumor control probability | (5) |
| TD50 (veff) | The tolerance dose corresponding to the veff to reach the 50% normal tissue complication probability | (6) |
| veff | Effective volume |
Radiobiological parameters used to calculate tumor control probability (TCP) and normal tissue complication probability (NTCP)
| Type | Organs | a | γ50 | TCD 50a / TD50b | α/β (endpoint) |
|---|---|---|---|---|---|
| Tumor | Prostate | –13 | 2.2 | 67.5 | 1.5 (local control) |
| Critical structures | Rectum | 8.33 | 2.66 | 80 | 5.4 (rectal bleeding) |
| Bladder | 2 | 3.63 | 80 | 7.5 (cystitis) |
aTCD50: The dose required for 50% probability of tumor control; bTD50: The tolerance dose corresponding to 50% complication probability of normal tissues.
Fig. 1.The overall procedure for implementing the bio-anatomical quality assurance (QA) that evaluates the dosimetric impacts of random and systematic errors.
Fig 2.Tumor control probability (TCP) and normal tissue complication probability (NTCP) mappings on CT images with principal structures for a patient with intact prostate, in various IMRT plan simulations of random and systematic errors. Red line: PTV; yellow line: rectum; green line: bladder: (a) an initial plan (MLCref), and plans employing (b) converted MLC field files from dynalog files (DLGref), (c) r-errors (DLG+1−1) with an +1 mm and –1 mm isocenter shift along the X- and the Y-orthogonal axes, (d) enlarged field (MLC+1+1) with the outward displacement of the multileaf collimator (MLC) leaves, (e) shrunken field (MLC−1−1) with the inward displacement of the MLC leaves and (f) difference in radiobiological effects of two plans (MLC+1+1-MLC−1−1).
Fig. 3.Tumor control probability (TCP) and normal tissue complication probability (NTCP) mappings on CT images with principal structures for a patient who underwent prostatectomy, in a simulation of random and systematic errors.
Variations in tumor control probability (TCP) from random errors (r-errors) and systematic errors (s-errors) for patients who had undergone prostatectomy and for those with intact prostate, based on the phenomenological logistic model
| TCP of prostatectomy patients (Gtectomy) (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient/Simulation | A | B | C | D | E | F | G | H | |
| DLGref | 71.61 | 67.49 | 70.56 | 71.58 | 71.63 | 71.20 | 72.53 | 72.48 | |
| DLG+1+1 | 71.71 | 67.52 | 69.99 | 71.52 | 71.23 | 71.14 | 72.14 | 72.46 | |
| DLG+1–1 | 71.17 | 67.06 | 70.40 | 67.06 | 71.26 | 70.87 | 72.26 | 71.91 | |
| DLG−1+1 | 71.62 | 67.47 | 69.88 | 71.59 | 71.28 | 71.18 | 72.27 | 72.53 | |
| DLG−1–1 | 71.02 | 67.05 | 70.30 | 71.14 | 71.55 | 70.92 | 72.42 | 71.94 | |
| Maximum variationa | –0.82 | –0.65 | –0.96 | –6.31 | –0.56 | –0.46 | –0.54 | –0.79 | |
| 0.15 | 0.047 | –0.23 | 0.01 | –0.12 | –0.031 | –0.16 | 0.061 | ||
| MLC−1–1 | 47.44 | 44.69 | 40.67 | 48.75 | 47.89 | 45.31 | 42.23 | 45.77 | |
| MLC+1+1 | 85.67 | 82.74 | 87.94 | 85.22 | 85.73 | 86.63 | 89.08 | 87.76 | |
| Maximum variation | –33.75 | –33.78 | –42.37 | –31.89 | –33.14 | –36.36 | –41.78 | –36.86 | |
| 19.64 | 22.60 | 24.64 | 19.05 | 19.68 | 21.68 | 22.81 | 21.08 | ||
| DLGref | 88.88 | 83.20 | 87.22 | 86.87 | 87.50 | ||||
| DLG+1+1 | 88.96 | 83.29 | 87.20 | 86.87 | 87.51 | ||||
| DLG+1–1 | 88.32 | 82.79 | 87.13 | 86.70 | 87.08 | ||||
| DLG−1+1 | 88.99 | 83.25 | 87.11 | 86.85 | 87.52 | ||||
| DLG−1–1 | 88.30 | 82.72 | 87.05 | 86.67 | 87.05 | ||||
| Maximum variation | 0.13 | 0.11 | –0.024 | –0.0061 | 0.02 | ||||
| –0.65 | –0.57 | –0.20 | –0.23 | –0.52 | |||||
| MLC−1–1 | 68.66 | 77.07 | 77.87 | 62.75 | 70.25 | ||||
| MLC+1+1 | 96.12 | 87.76 | 92.02 | 95.70 | 94.57 | ||||
| Maximum variation | –22.75 | –7.37 | –10.72 | –27.77 | –19.72 | ||||
| 8.15 | 5.48 | 5.50 | 10.16 | 8.08 | |||||
aMaximum variation: maximum error that is negative and positive difference.
Variations in normal tissue complication probability (NTCP) from random (r-errors) and systematic errors (s-errors) in the rectum for patients who had undergone prostatectomy and for those with intact prostate, based on the phenomenological logistic model
| NTCP of prostatectomy patients (Gtectomy) – rectum (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient/simulation | A | B | C | D | E | F | G | H | |
| DLGref | 2.64 | 4.40 | 4.44 | 4.81 | 5.54 | 5.01 | 6.23 | 5.98 | |
| DLG+1+1 | 3.26 | 4.88 | 5.27 | 5.30 | 6.77 | 5.82 | 6.84 | 6.48 | |
| DLG+1–1 | 2.34 | 3.74 | 4.05 | 3.74 | 5.19 | 4.56 | 5.56 | 5.10 | |
| DLG−1+1 | 3.17 | 4.79 | 5.22 | 5.31 | 6.72 | 5.83 | 6.92 | 6.50 | |
| DLG−1–1 | 2.25 | 3.72 | 4.02 | 4.12 | 5.14 | 4.57 | 5.62 | 5.13 | |
| Maximum variationa | –14.70 | –15.60 | –9.46 | –22.15 | –7.08 | –8.86 | –10.84 | –14.64 | |
| 23.76 | 10.82 | 18.71 | 10.38 | 22.39 | 16.46 | 11.04 | 8.81 | ||
| MLC−1-1 | 0.89 | 1.70 | 1.38 | 1.89 | 2.16 | 1.80 | 2.17 | 2.06 | |
| MLC+1+1 | 5.79 | 9.26 | 10.69 | 9.51 | 11.49 | 10.92 | 14.82 | 12.93 | |
| Maximum variation | –66.09 | –61.36 | –68.81 | –60.62 | –61.03 | –64.07 | –65.16 | –65.54 | |
| 119.88 | 110.14 | 140.78 | 97.88 | 107.59 | 118.15 | 137.79 | 116.32 | ||
| DLGref | 8.37 | 7.40 | 15.03 | 11.90 | 15.38 | ||||
| DLG+1+1 | 9.07 | 8.17 | 16.75 | 14.16 | 16.49 | ||||
| DLG+1–1 | 6.40 | 5.89 | 13.86 | 10.99 | 13.05 | ||||
| DLG−1+1 | 9.07 | 5.76 | 16.74 | 13.98 | 16.19 | ||||
| DLG−1–1 | 6.57 | 5.76 | 13.86 | 10.83 | 12.76 | ||||
| Maximum variation | –23.51 | –22.11 | –7.82 | –8.96 | –17.03 | ||||
| 8.46 | 10.38 | 11.37 | 19.01 | 7.21 | |||||
| MLC−1–1 | 2.20 | 4.81 | 8.32 | 3.48 | 5.68 | ||||
| MLC+1+1 | 19.60 | 10.86 | 21.90 | 25.21 | 27.87 | ||||
| Maximum variation | –73.74 | –35.03 | –44.66 | –70.77 | –63.05 | ||||
| 134.28 | 46.73 | 45.65 | 111.86 | 81.17 | |||||
aMaximum variation: maximum error that is negative and positive difference.
Variations in normal tissue complication probability (NTCP) from random (r-errors) and systematic errors (s-errors) in the bladder for patients who had undergone prostatectomy and for those with intact prostate, based on the phenomenological logistic model
| NTCP of prostatectomy patients (Gtectomy) – bladder (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient/simulation | A | B | C | D | E | F | G | H | |
| DLGref | 3.87 | 3.44 | 7.74 | 4.78 | 3.87 | 2.98 | 8.11 | 3.03 | |
| DLG+1+1 | 3.69 | 3.32 | 7.22 | 4.62 | 3.52 | 2.81 | 7.57 | 2.93 | |
| DLG+1–1 | 3.99 | 3.64 | 8.03 | 5.07 | 3.99 | 3.08 | 8.81 | 3.20 | |
| DLG−1+1 | 3.69 | 3.35 | 7.17 | 4.59 | 3.51 | 2.84 | 7.72 | 2.92 | |
| DLG−1–1 | 3.99 | 3.67 | 7.99 | 5.05 | 4.02 | 3.12 | 8.91 | 3.20 | |
| Maximum variation | –4.81 | –3.47 | –7.45 | –3.96 | –9.31 | –5.67 | –6.63 | –3.35 | |
| 3.13 | 6.67 | 3.72 | 6.09 | 4.01 | 4.64 | 9.77 | 5.89 | ||
| MLC−1–1 | 1.38 | 1.18 | 2.05 | 1.75 | 1.27 | 0.86 | 1.95 | 0.84 | |
| MLC+1+1 | 8.32 | 8.31 | 21.90 | 10.69 | 9.71 | 8.01 | 25.02 | 8.32 | |
| Maximum variation | –64.35 | –65.75 | –73.55 | –63.36 | –67.09 | –71.13 | –75.92 | –72.29 | |
| 114.98 | 141.14 | 182.76 | 123.81 | 151.24 | 168.79 | 208.38 | 175.10 | ||
| DLGref | 16.98 | 6.77 | 14.27 | 28.81 | 9.06 | ||||
| DLG+1+1 | 16.56 | 6.45 | 13.86 | 27.71 | 8.81 | ||||
| DLG+1–1 | 18.00 | 7.28 | 14.57 | 29.10 | 9.46 | ||||
| DLG−1+1 | 16.54 | 6.50 | 13.82 | 27.99 | 8.90 | ||||
| DLG−1–1 | 18.02 | 7.34 | 14.53 | 29.40 | 9.55 | ||||
| Maximum variation | –2.56 | –4.75 | –3.12 | –3.82 | −2.69 | ||||
| 6.16 | 8.35 | 2.09 | 2.05 | 5.47 | |||||
| MLC−1–1 | 5.44 | 4.87 | 8.98 | 9.57 | 3.73 | ||||
| MLC+1+1 | 32.70 | 8.98 | 19.85 | 54.03 | 14.04 | ||||
| Maximum variation | –67.97 | –28.03 | –37.06 | –66.78 | −58.86 | ||||
| 92.62 | 32.66 | 39.14 | 87.52 | 54.98 | |||||
aMaximum variation: maximum error that is negative and positive difference.